Most people find out they have a migraine when the pain starts. Wavefront tells you 36 hours earlier — at home, every night, while you're still asleep.
Put in your Bluetooth EEG buds. Sleep. Wake up with a prediction. No clinic. No gel cap. No prescription. A new category of Bluetooth EEG sleep device reads your brain overnight. The consumer app is the entry point. The platform is the opportunity.
Wavefront is a software intelligence layer that sits on top of existing consumer EEG hardware. The consumer app proves the signal. The platform monetizes it — through pharma data licensing, clinical trial infrastructure, and hardware partnerships.
Bluetooth EEG sleep devices, Oura Ring, Apple Watch. We own no hardware. Wavefront is a software intelligence layer that runs on top of emerging consumer EEG hardware and existing health wearables.
RHR, HRV, respiratory rate, wrist temperature, gait asymmetry. Walking asymmetry now validated as a CSD-specific marker — spikes on brainstem aura days, silent on pain-only days. No new devices required.
Barometric pressure, temperature, humidity via Open-Meteo API. Already proven: r=+0.81 correlation between pressure drop and SW/hr collapse.
EEG Biomarker · Prediction Engine · Pathway Classifier · Clinical Data Infrastructure
iOS app for migraine patients. Subscription model. Proves the signal, builds the dataset, establishes brand. Entry point to the platform.
EEG biomarker data licensed to Lilly, AbbVie, Amgen for clinical trial design, drug timing optimization, and patient stratification.
Objective outcome measurement for migraine trials. EEG hardware partnership. Hospital and neurology clinic tools. FDA Breakthrough Device pathway.
Most prediction systems apply one number to everyone. Wavefront does the opposite — it learns your brain. 60 SW/hr is the threshold that predicted the founder's migraines. Yours might be different. The platform derives your personal threshold from your own sleep data, then watches for it every night.
Each bar below represents one hour of deep sleep brain activity — measured in slow waves per hour (SW/hr). A full healthy bar means the brain is in deep, restorative sleep. A collapsed bar means the brain is too electrically active to generate slow waves — the neurological signature that a migraine is building. Watch what happens in the three nights before the attack.
2 CONFIRMED INTERCEPTIONS — MAR 11 & MAR 17, 2026
Mar 11: SW/hr 47 + HRV 12.3ms. Alert fired. Medication taken early. Mar 12: rebounded to 126. No migraine. Mar 17: SW/hr 45, below auto-calculated threshold. Alert. Confirmed migraine onset same day. Prediction-to-outcome loop documented twice.
Slow waves are the cortical recovery signal of deep sleep. In migraine, the cortex becomes chronically hyperexcitable. Slow waves collapse as excitability rises — days before pain begins. This is measurable, repeatable, and predictive.
No wristband measures this. No existing consumer software reads it. Wavefront is the first to operationalize this signal into a prediction engine.
The 60 SW/hr threshold that predicted the founder's migraine was not pulled from a textbook. It was derived from her own 16 nights of EEG data — her baseline, her variability, her brain. Someone else's threshold might be 40. Or 80. A universal number applied to every patient would be less accurate for everyone.
"This is not a population average applied to individuals. This is each patient's own neurological pattern, learned from their own data, predicting their own attacks. That is what makes it defensible as IP — and more accurate than anything else on the market."
— M.E. Esquivel, Inventor · Patent Pending
The consumer app generates users and data. The data generates pharma licensing revenue. The methodology generates clinical infrastructure and partnership opportunities. Each stream reinforces the others.
Eli Lilly (Vyepti), AbbVie (Qulipta), Amgen (Aimovig), Pfizer — all have major migraine portfolios and need objective biomarker data for clinical trial design, patient stratification, and drug timing optimization.
Current migraine trials rely on patient-reported pain diaries — highly subjective outcome measures. An objective EEG-based outcome measure changes trial design entirely. Wavefront becomes the measurement platform for next-generation migraine trials.
Consumer EEG hardware manufacturers make the device. Wavefront has validated that device as a migraine predictor. A formal partnership or licensing agreement makes Wavefront the recommended software companion for every unit sold.
Patient-generated EEG reports between appointments. Medication efficacy correlation. Objective between-visit data for neurologists managing chronic migraine patients. SaaS subscription for neurology practices.
Direct-to-patient migraine prediction app. Subscription model. Builds the dataset, proves the signal to institutional buyers, establishes brand authority in the migraine community.
50-patient validation study unlocks application for FDA Breakthrough Device designation. This designation fast-tracks review and transforms the acquisition value of the company.
Vision went dark while driving. Diagnosed: chronic migraine with brainstem aura. The event that made building a warning system not optional.
Bluetooth EEG sleep device deployed for nightly recording. Timestamped data collection begins. This is when the invention moved from concept to active operation.
Baseline 162 SW/hr established. 94% signal crash on migraine day (Mar 8) confirmed. Dynamic threshold auto-calculated from 9 clean nights. Two confirmed interceptions (Mar 11, Mar 17). Cortical buildup and illness-triggered pathways both documented. Walking asymmetry identified as CSD-specific biomarker. Working prototype live, functional, and continuously learning.
Patent Pending — Filed Mar 18, 2026 · 22 claims · Priority date secured. Two new claims (gait asymmetry as CSD biomarker; pathway classification method) in attorney review. 16 nights of continuous EEG data. Investor site live. Indiegogo campaign in preparation.
Native iOS app with HealthKit integration. Begin structured data collection. First meetings with pharma business development teams.
IRB-approved study at academic medical center. Peer-reviewed publication. NIH SBIR application. FDA Breakthrough Device application initiated.
Validated biomarker + published study + growing patient dataset creates the foundation for a first data licensing agreement with a major migraine pharma company.
Pre-seed capital converts a validated prototype and a confirmed biomarker into a market-ready platform.
Funds the iOS app development and initial patient data collection.
Funds the full platform build including clinical data infrastructure, IRB study, and first pharma business development activity.
The right partner understands that a validated neurological biomarker — discovered by a patient, confirmed in real data, with a working prototype — is a rare asset at the pre-seed stage.
Early-stage funds focused on digital health, neurotechnology, or women's health. Wavefront sits at the intersection of wearables, AI, clinical neurology, and pharma data.
$100k — $2MIndividuals with personal connection to migraine, neurology, or women's health. Operators who've built health tech companies.
$5k — $250kPharma companies with migraine portfolios (Lilly, AbbVie, Amgen). Consumer EEG hardware companies. Clinical research organizations.
Strategic + CapitalAmerican Migraine Foundation. PCORI. NIH SBIR/STTR programs. Organizations funding patient-led innovation.
Grant + Program SupportWavefront was not built by a startup team chasing a market. It was built by a patient with an engineering background, an MBA, and 30 years of living with migraine — who identified a neurological signal in her own brain that no consumer product had ever detected.
The prototype runs on her own EEG data. The threshold came from her own brain — auto-calculated nightly from her own clean sleep data. Two confirmed interceptions happened in her own nervous system. The walking asymmetry signal was discovered in her own body. This is not theoretical — it is personal.
This is a founder who cannot walk away from the problem. The product is the difference between a normal day and a lost one.
A validated biomarker. A working prototype. A confirmed interception. A founder who cannot stop. If you've read this far, you understand the opportunity.
Tell us who you are and what you're looking for. We'll respond within 48 hours.